SecBot SecBot
SECBOTREPLAY Home › Report › TNGX

TNGX · Tango Therapeutics is holding its annual shareholder meeting to vote on…

Tango Therapeutics, Inc. · DEFA14A filed Apr 17, 2026 at 07:42 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Apr 17, 2026 at 07:42 ET

Tango Therapeutics is holding its annual shareholder meeting to vote on the re-election of three Class II directors, ratification of its auditor, and approval of executive compensation. This is a routine annual proxy filing, and recent executive changes suggest ongoing leadership transitions.

  • Shareholders will vote on the re-election of directors Malte Peters, M.D., Kanishka Pothula, and Mace Rothenberg, M.D.
  • The board recommends ratifying PricewaterhouseCoopers LLP as the independent auditor.
  • The board recommends approving the compensation of named executive officers.
  • Recent executive changes include the appointment of Matthew Gall as CFO and Jessica Newcomb as principal accounting officer.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access